BiOrion is a Dutch biopharmaceutical company, developing innovative therapeutics and in-vivo diagnostics for fibrotic diseases that possess the PDGF-ß-receptor as their crucial target.

These PDGF-ß-receptors are abundantly expressed on activated fibroblasts, present in fibrotic tissue such as in liver fibrosis, kidney fibrosis, and idiopathic pulmonary fibrosis (IPF). Moreover, these fibroblasts are also present in many stroma-rich cancers, such as breast cancer.